Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting
Key Highlights
- ➤Caribou will present vispa-cel and CB-011 data at three 2026 ASH sessions
- ➤Caribou plans to discontinue vispa-cel and CB-011 development activities
- ➤Caribou is exploring strategic alternatives to maximize stockholder value
- ➤Vispa-cel data address multi-year complete remissions in relapsed/refractory B-NHL
- ➤CB-011 data address deep, durable responses in heavily pretreated relapsed/refractory multiple myeloma
Expert Statements
Mehdi Hamadani, Professor of Medicine and Section Chief of Hematologic Malignancies at Medical College of Wisconsin; ANTLER trial investigator
“Multi-year complete remissions achieved with vispa-cel, an off-the-shelf CAR-T cell therapy, in patients with relapsed/refractory B cell non-Hodgkin lymphoma: an analysis of patients who are progression-free at ≥12 months (ANTLER trial)”
Adriana Rossi, Director of CAR-T and Stem Cell Transplant Clinical Program at the Center of Excellence for Multiple Myeloma at Mt Sinai; CaMMouflage trial investigator
“Deep and durable responses achieved with CB-011, an off-the-shelf CAR-T cell therapy, for heavily pretreated patients with relapsed/refractory multiple myeloma (CaMMouflage trial)”
Mohamad Cherry, Medical Director of Hematology at Atlantic Health; ANTLER trial investigator
“Vispa-cel, an off-the-shelf CAR-T cell therapy, in patients with large B cell lymphoma who relapsed after prior CD19-directed treatment (ANTLER trial)”
BERKELEY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU) today announced that vispa-cel and CB-011 clinical abstracts have been accepted for two oral presentations and one poster presentation at the 2026 American Society of Hematology (ASH) Annual Meeting, which will be held December 12-15, 2026 in New Orleans, Louisiana.
The accepted abstracts were submitted prior to Caribou’s announcement of plans to explore strategic alternatives and discontinue further development activities for its two allogeneic CAR-T cell therapy programs, vispa-cel for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin lymphoma and CB-011 for the treatment of r/r multiple myeloma, due to the current financing environment for allogeneic CAR-T cell therapies. Investigators will present data from both programs to share important clinical findings with the medical and scientific community.
Get started
Create a free account to read the full story.